8-K: Medicus Pharma to Acquire Antev Ltd. in \$75 Million Share Exchange Deal

Medicus Pharma Ltd. has entered into a binding letter of intent to acquire Antev Ltd., a clinical-stage biotech company, in a share exchange transaction valued at approximately \$75 million.

Summary

• Medicus Pharma Ltd. has announced a binding letter of intent to acquire Antev Ltd.
• The acquisition will be a share exchange, with Antev shareholders receiving approximately 19% of Medicus's issued and outstanding common shares.
• Antev shareholders could also receive up to \$65 million in contingent payments based on future FDA approvals.
• The total deal value is estimated at approximately \$75 million.
• Antev is developing Teverelix, a next-generation GnRH antagonist, targeting acute urinary retention and advanced prostate cancer with high cardiovascular risk.
• The transaction is expected to close before the end of June 2025, pending due diligence, definitive agreements, and regulatory approvals.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the potential of the acquisition to enhance Medicus Pharma's pipeline and address significant market opportunities. However, risks associated with regulatory approvals and clinical development temper the overall sentiment.

Positives

• The acquisition of Antev provides Medicus Pharma with a promising drug candidate, Teverelix, targeting significant market opportunities.
• Teverelix has the potential to be a first-in-class treatment for acute urinary retention and a best-in-class treatment for advanced prostate cancer patients with high cardiovascular risk.
• The deal structure includes contingent payments, aligning the interests of Antev shareholders with the successful development and approval of Teverelix.
• Medicus Pharma gains access to Antev's FDA-approved Phase 2b study designs for both acute urinary retention and advanced prostate cancer indications.

Negatives

• The transaction is subject to customary closing conditions, including due diligence, negotiation of definitive agreements, and regulatory approvals, and there is no guarantee that the deal will be completed.
• The contingent payments are dependent on future FDA approvals, which are subject to regulatory risks and uncertainties.
• Antev's Phase 2a study in advanced prostate cancer did not meet its secondary endpoint of maintaining castration levels of testosterone suppression above 90% by Day 42.

Risks

• The successful negotiation and execution of a definitive agreement are not guaranteed.
• The transaction may not close on the expected timeline or at all.
• The development and commercialization of Teverelix are subject to regulatory and clinical risks.
• The potential market opportunity for Teverelix may not materialize as expected.
• The interim analysis of SkinJect Inc's SKNJCT-003 study is preliminary and may not correlate with the final study results.

Future Outlook

Medicus Pharma aims to close the acquisition of Antev by the end of June 2025 and advance the clinical development of Teverelix, targeting significant market opportunities in acute urinary retention and advanced prostate cancer.

Management Comments

• 'The LOI to acquire Antev represents strategic depth in our drug development program,' stated Dr. Raza Bokhari, Executive Chairman & CEO.
• Dr. Bokhari believes Teverelix is relatively derisked and well-positioned to become a first-in-class product, representing a significant market opportunity.

Industry Context

The acquisition reflects a trend in the biotech industry of companies acquiring promising drug candidates to expand their pipelines and address unmet medical needs in areas such as oncology and urology.

Comparison to Industry Standards

• The \$75 million deal value is comparable to other acquisitions of clinical-stage biotech companies with promising drug candidates.
• The contingent payment structure is a common practice in biotech acquisitions, aligning the interests of the acquired company's shareholders with the successful development and commercialization of the drug candidate.
• Antev's focus on developing Teverelix as a first-in-class treatment for acute urinary retention and a best-in-class treatment for advanced prostate cancer aligns with the industry's focus on developing innovative therapies for unmet medical needs.
• Companies like Astellas and Pfizer have similar drugs in their portfolio.

Stakeholder Impact

• Shareholders of Medicus Pharma may see potential long-term value creation through the acquisition of Antev and the development of Teverelix.
• Antev's employees may benefit from the resources and expertise of Medicus Pharma.
• Patients with acute urinary retention and advanced prostate cancer may benefit from the development of new and improved treatment options.
• The acquisition could impact Medicus Pharma's suppliers and creditors, depending on the terms of the transaction and the company's future financial performance.

Next Steps

• Medicus Pharma will conduct due diligence on Antev Ltd.
• The companies will negotiate and enter into a definitive agreement.
• The transaction will be subject to corporate, regulatory, and third-party approvals.
• The companies will work towards closing the transaction before the end of June 2025.

Key Dates

Keywords

acquisition, Antev Ltd, Medicus Pharma, Teverelix, prostate cancer, acute urinary retention, GnRH antagonist, biotech, pharmaceuticals, FDA approval